Akero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) VP Patrick Lamy sold 919 shares of Akero Therapeutics stock in a transaction that occurred on Tuesday, June 10th. The stock was sold at an average price of $54.00, for a total transaction of $49,626.00. Following the completion of the transaction, the vice president now directly owns 32,573 shares in the company, valued at approximately $1,758,942. The trade was a 2.74% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Patrick Lamy also recently made the following trade(s):
- On Monday, June 2nd, Patrick Lamy sold 4,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $50.31, for a total transaction of $201,240.00.
- On Thursday, May 22nd, Patrick Lamy sold 4,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $50.00, for a total transaction of $200,000.00.
- On Wednesday, May 7th, Patrick Lamy sold 8,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $42.49, for a total transaction of $339,920.00.
Akero Therapeutics Price Performance
NASDAQ:AKRO traded up $2.06 during trading hours on Friday, reaching $55.62. 2,224,332 shares of the company were exchanged, compared to its average volume of 1,009,425. The company has a current ratio of 17.25, a quick ratio of 17.25 and a debt-to-equity ratio of 0.05. The stock's 50-day moving average is $43.96 and its 200-day moving average is $40.36. The firm has a market cap of $4.43 billion, a PE ratio of -14.83 and a beta of -0.16. Akero Therapeutics, Inc. has a twelve month low of $21.02 and a twelve month high of $58.40.
Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The company reported $0.90 earnings per share for the quarter, topping analysts' consensus estimates of ($1.01) by $1.91. On average, sell-side analysts anticipate that Akero Therapeutics, Inc. will post -3.99 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Akero Therapeutics
Large investors have recently added to or reduced their stakes in the stock. Tema Etfs LLC acquired a new position in Akero Therapeutics during the fourth quarter worth $894,000. Cubist Systematic Strategies LLC purchased a new stake in shares of Akero Therapeutics during the fourth quarter worth $840,000. RTW Investments LP grew its holdings in shares of Akero Therapeutics by 15.9% during the fourth quarter. RTW Investments LP now owns 6,859,823 shares of the company's stock worth $190,840,000 after buying an additional 940,388 shares in the last quarter. Ameriprise Financial Inc. purchased a new stake in shares of Akero Therapeutics during the fourth quarter worth $422,000. Finally, Two Sigma Advisers LP grew its holdings in shares of Akero Therapeutics by 195.7% during the fourth quarter. Two Sigma Advisers LP now owns 41,100 shares of the company's stock worth $1,143,000 after buying an additional 27,200 shares in the last quarter.
Wall Street Analyst Weigh In
Several brokerages have commented on AKRO. Citigroup decreased their price objective on shares of Akero Therapeutics from $80.00 to $78.00 and set a "buy" rating for the company in a research note on Tuesday, May 13th. HC Wainwright boosted their target price on shares of Akero Therapeutics from $72.00 to $75.00 and gave the company a "buy" rating in a research note on Monday, March 3rd. Bank of America boosted their target price on shares of Akero Therapeutics from $63.00 to $64.00 and gave the company a "buy" rating in a research note on Tuesday, May 27th. Finally, Morgan Stanley reiterated an "overweight" rating on shares of Akero Therapeutics in a research note on Sunday, March 2nd. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Akero Therapeutics has a consensus rating of "Buy" and an average target price of $82.50.
Check Out Our Latest Analysis on Akero Therapeutics
About Akero Therapeutics
(
Get Free Report)
Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.
Further Reading
Before you consider Akero Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Akero Therapeutics wasn't on the list.
While Akero Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
